Join Medcilon at the 2022 SAPA Annual Conference

We are very pleased to announce that Medicilon will participate in the SAPA Annual Conference. It kicks off on September 30, 2022 in New Jersey, the Medicilon American team will be present throughout the event. We sincerely invite you to come to have a discussion with us!

About 2022 SAPA Annual Conference

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 in New Jersey, USA. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members. The SAPA Annual Conference is a great platform with events including presentations and panel discussions by distinguished speakers and panelists from academia and industry, providing opportunities for scientific exchange, public health education, networking, career development and business collaboration. The theme of this year's conference is "Building a Platform for Innovation and Growth in Medicine and Biotechnology", covering the latest advances in drug discovery, emerging therapeutic modalities and cell and gene therapies, clinical development and more.

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

Medicilon Drug Discovery Services

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

Medicilon Cell Therapy Drug Service Platform

Cell and gene therapy (CGT) has developed rapidly in recent years, offering the possibility to cure many refractory malignant tumors. Driven by technology, capital and policy, the global CGT industry is rapidly heating up, and a large number of CGT drugs have entered the clinical stage, providing new treatment concepts and ideas for refractory diseases.

Medicilon has established a complete research and development platform for cell and gene therapy drugs, which can provide one-stop services such as pharmacological efficacy, biodistribution and safety evaluation for cell and gene therapy products. Using a variety of animal models and advanced analytical techniques, Medicilon has completed a number of preclinical development projects of gene and cellular immunotherapy regimens for its clients, taking into account the characteristics of different research projects.

Medicilon has built a one-step platform for the preclinical research and development of cellular immunotherapy drugs, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK, using rich animal models and a variety of advanced analytical techniques, comprehensively considering the characteristics of different research projects. Has completed several preclinical development projects for immunotherapy regimens for clients.